Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tari Ann King, M.D.

Co-Author

This page shows the publications co-authored by Tari King and Alison Laws.
Connection Strength

4.107
  1. ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. Ann Surg Oncol. 2022 Mar; 29(3):1668-1669.
    View in: PubMed
    Score: 0.990
  2. Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. Ann Surg Oncol. 2022 Mar; 29(3):1660-1667.
    View in: PubMed
    Score: 0.960
  3. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Nov; 26(12):3846-3855.
    View in: PubMed
    Score: 0.821
  4. Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. Ann Surg Oncol. 2018 Nov; 25(12):3548-3555.
    View in: PubMed
    Score: 0.775
  5. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227.
    View in: PubMed
    Score: 0.224
  6. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. Ann Surg Oncol. 2021 Mar; 28(3):1358-1367.
    View in: PubMed
    Score: 0.223
  7. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2021 Nov; 28(12):7347-7355.
    View in: PubMed
    Score: 0.058
  8. Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. Mod Pathol. 2021 05; 34(5):875-882.
    View in: PubMed
    Score: 0.057
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.